At a glance
- Originator Pfizer
- Class Antiasthmatics; Imidazoles; Small molecules; Sulfides
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 05 Sep 2006 Discontinued - Phase-II for Asthma in USA (PO)
- 05 Sep 2006 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA (PO)
- 31 Jul 2002 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (PO)